Effect of Bile Acids on Satiety, Cell Function and Body Weight in Patients With Obesity and Abnormal Satiety Phenotype
Phase 1
Completed
- Conditions
- HealthyObesity
- Interventions
- Dietary Supplement: Ileocolonic-release conjugated bile acidDrug: Placebo
- Registration Number
- NCT05314374
- Lead Sponsor
- Mayo Clinic
- Brief Summary
The purpose of this research is to study the effect of the study drug (a conjugated bile acid dietary supplement) or placebo on cell function, hormones and body weight.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 35
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Bile Acid Supplement Group Ileocolonic-release conjugated bile acid Subjects with obesity and abnormal satiety phenotype will receive ileocolonic-release conjugated bile acid supplements Placebo Group Placebo Subjects with obesity and abnormal satiety phenotype will receive matching-placebo
- Primary Outcome Measures
Name Time Method Glucagon-Like Peptide-1 (GLP-1) 90 days The number of participants that provided a blood sample for GLP-1 (ug/ml) .
Peptide Trosin Tyrosine (PYY) Hormone 90 days The number of participants that provided a blood sample for PYY.
- Secondary Outcome Measures
Name Time Method Change in Weight Baseline, 12 weeks Change in weight, measured in kilograms (kg), from baseline visit to 12 weeks.
Trial Locations
- Locations (1)
Mayo Clinic in Rochester
🇺🇸Rochester, Minnesota, United States